Your browser doesn't support javascript.
loading
Should tocilizumab be the first line treatment for neuromyelitis optica together with rituximab? / ¿Debería ser el tocilizumab el tratamiento de primera línea para la neuromielitis óptica junto con el rituximab?
Sawaya, R; Saab, G; Moussa, H.
Affiliation
  • Sawaya, R; American University of Beirut Medical Center. Beirut. Lebanon
  • Saab, G; American University of Beirut Medical Center. Beirut. Lebanon
  • Moussa, H; American University of Beirut Medical Center. Beirut. Lebanon
Neurología (Barc., Ed. impr.) ; 36(8): 642-643, octubre 2021.
Article in English | IBECS | ID: ibc-220120
Responsible library: ES1.1
Localization: ES15.1 - BNCS
Subject(s)
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Neuromyelitis Optica / Antibodies, Monoclonal, Humanized / Rituximab Limits: Humans Language: English Journal: Neurología (Barc., Ed. impr.) Year: 2021 Document type: Article Institution/Affiliation country: American University of Beirut Medical Center/Lebanon
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Neuromyelitis Optica / Antibodies, Monoclonal, Humanized / Rituximab Limits: Humans Language: English Journal: Neurología (Barc., Ed. impr.) Year: 2021 Document type: Article Institution/Affiliation country: American University of Beirut Medical Center/Lebanon